Breaking Finance News

Commerzbank AG announced Fresenius (ETR:FRE), boosting its stock price target to 81.00EUR today

Having a price of 70.00EUR, Fresenius (ETR:FRE) traded 0.00% even on the day. With the last close up 0.00% relative to the two hundred day moving average, compared to the Standard & Poor’s 500 Index which has decreased -0.01% over the same period. The company has logged a 50-day average of 0.00EUR and 200-day moving average of 0.00EUR. Trading volume was held steady, with 0 shares of FRE changing hands on par with the typical 0 shares.

In an issued report on 9/20/2016 Commerzbank AG increased the target price of Fresenius (ETR:FRE) from 0EUR to 81EUR indicating a possible upsideof 0.16%.

On 9/19/2016, Commerzbank AG released a statement about Fresenius(ETR:FRE) bumped the target price from 0.00EUR to 81.00EUR that indicated a possible upside of 0.16%.

See Graph Below:

Fresenius (ETR:FRE)

Fresenius has a 52 week low of 0.00EUR and a one-year high of 0.00EUR and has a total market value of 0.0 EUR.

Brief Synopsis About Fresenius (ETR:FRE)

Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments include Fresenius Medical Care; Fresenius Kabi; Fresenius Helios and Fresenius Vamed. The Fresenius Medical Care segment provides dialysis care and dialysis products for patients with chronic kidney failure. The Fresenius Kabi segment is engaged in provision of intravenously administered drugs (IV drugs), infusion therapies, and clinical nutrition and outpatient care. The Fresenius Helios segment is a private hospital operator and operates 72 clinics. The Fresenius Vamed segment provides engineering and services for hospitals and other health care facilities internationally.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *